Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China
Cancer Medicine · 2025
DOI: 10.1002/cam4.70542 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Chen Liao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Chongqing University Jiangjin Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Uncommon EGFR mutations are a kind of heterogeneous group of mutations with various responses to EGFR‐TKIs and are often excluded from most prospective clinical trials. In this real‐world retrospective study, we retrospectively compared the efficacy and safety of chemotherapy or various generations of EGFR‐TKIs as first‐line therapy in NSCLC Chinese patients harboring non‐ex 20 ins uncommon EGFR mutations.
Methods
We enrolled 139 NSCLC patients with non‐ex 20 ins uncommon EGFR mutations in this study retrospectively. Patients' clinical characteristics and the efficacy and safety of different first‐line therapies were analyzed and compared.
Results
Our data reviewed that for first‐line therapy, NSCLC patients harboring non‐ex 20 ins uncommon EGFR mutations benefited more from EGFR‐TKIs compared with chemotherapy. Afatinib performed with great efficacy for the majority of non‐ex 20 ins uncommon EGFR mutations ( N = 43, ORR = 41.86%, mPFS = 13.5 months, mOS = 20.8 months), especially in L861Q mutation (mPFS = 18.4 months). Osimertinib also demonstrated efficacy in patients harboring non‐ex 20 ins uncommon EGFR mutations ( N = 36, ORR = 27.78%, mPFS = 10.0 months, mOS = 21.0 months), especially in those without L861Q and G719X mutations (mPFS = 12.1 months). When treated with afatinib, patients harboring non‐ex 20 ins uncommon EGFR mutations should pay attention to the management of safety, especially for gastrointestinal‐related AE and rash, while osimertinib was safer.
Conclusion
Taking into account both efficacy and safety, afatinib and osimertinib are better choices than chemotherapy and first‐generation EGFR‐TKIs for NSCLC patients with non‐ex 20 ins uncommon EGFR mutations. L861Q showed a trend toward a better response to afatinib, while in those without L861Q and G719X mutations, osimertinib might be a better choice. Safety also should be a concern when choosing EGFR‐TKI for treatment, patients should pay attention to the management of safety when using afatinib while osimertinib is safer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.
- Department of Respiratory and Critical Care Medicine, Xinqiao Hospital, Army Medical University, Chongqing, China.
- Department of Respiratory and Critical Care Medicine, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Clinical Laboratory Medicine, Chongqing University Jiangjin Hospital, Chongqing, China.
ORCID-Profile: Li Bai, Qingle Liang, Yong He, Yubo Wang
Zitieren
APA
Liao, C., Bai, L., He, T., Liang, Q., Hu, D., Lei, S., He, Y., & Wang, Y. (2025). Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China. Cancer Medicine. https://doi.org/10.1002/cam4.70542
Vancouver
Liao C, Bai L, He T, Liang Q, Hu D, Lei S, et al. Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China. Cancer Medicine. 2025. doi:10.1002/cam4.70542
BibTeX
@article{Liao2025,
author = {Liao, Chen and Bai, Li and He, Tingting and Liang, Qingle and Hu, Defeng and Lei, Shipeng and He, Yong and Wang, Yubo},
title = {Efficacy and Safety of Chemotherapy or EGFR ‐ TKIs as First‐Line Therapy in NSCLC Patients Harboring Non‐Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70542}
}
EUVIMED